<DOC>
	<DOCNO>NCT03032172</DOCNO>
	<brief_summary>This multi-center , exploratory , non-comparative open-label study investigate safety , tolerability , pharmacokinetic ( PK ) PK/pharmacodynamic ( PD ) relationship RO7034067 adult child Type 2 Type 3 Spinal Muscular Atrophy ( SMA ) previously treat survival motor neuron 2 ( SMN2 ) -targeting therapy .</brief_summary>
	<brief_title>A Study RO7034067 Adult Pediatric Participants With Spinal Muscular Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Confirmed diagnosis 5qautosomal recessive SMA Previous participation study SMN2targeting antisense oligonucleotide SMN2 splice modifier RO7034067 Negative blood pregnancy test screening agreement comply measure prevent pregnancy restriction sperm donation Inability meet study requirement Concomitant participation investigational drug device study Previous participation SMN2targeting antisense oligonucleotide SMN2 splice modifier study RO7034067 within 90 day prior screen Previous participation investigational drug device study , SMN2 target antisense oligonucleotide SMN2 splice modifier study , within 90 day prior screen , 5 halflives drug , whichever longer Any history gene cell therapy Unstable gastrointestinal , renal , hepatic , endocrine , cardiovascular system disease consider clinically significant Investigator Presence clinically significant electrocardiogram ( ECG ) abnormality study drug administration indicate safety risk participant determine Investigator . Significant risk suicidal behavior , opinion Investigator assess CSSRS Any major illness within one month screen examination febrile illness within one week prior screen first dose administration Recently initiate treatment ( within less [ &lt; ] 6 month prior enrollment ) oral salbutamol another beta 2adrenergic agonist take orally Any prior use chloroquine , hydroxychloroquine , retigabin , vigabatrin thioridazine , allow Ascertained presumptive hypersensitivity ( e.g. , anaphylactic reaction ) RO7034067 constituent formulation Concomitant disease condition could interfere , treatment might interfere , conduct study , would , opinion Investigator , pose unacceptable risk participant study Recent history ( less one year ) ophthalmological disease would interfere conduct study assess ophthalmologist . Participants Organic Cation Transporter Optical Coherence Tomography ( OCT ) measurement sufficient quality obtain screening enrol</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>